Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$4.1 million.

  • Janux Therapeutics' Net Cash Flow fell 13355.11% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 million, marking a year-over-year increase of 12531.76%. This contributed to the annual value of $411.4 million for FY2024, which is 137680.71% up from last year.
  • Latest data reveals that Janux Therapeutics reported Net Cash Flow of -$4.1 million as of Q3 2025, which was down 13355.11% from -$21.3 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Net Cash Flow ranged from a high of $403.9 million in Q4 2024 and a low of -$356.9 million during Q1 2025
  • Its 5-year average for Net Cash Flow is $2.2 million, with a median of $2.1 million in 2023.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 1891756.27% in 2021, then soared by 1957126.16% in 2024.
  • Quarter analysis of 5 years shows Janux Therapeutics' Net Cash Flow stood at -$3.0 million in 2021, then crashed by 345.54% to -$13.3 million in 2022, then soared by 115.41% to $2.1 million in 2023, then soared by 19571.26% to $403.9 million in 2024, then tumbled by 101.0% to -$4.1 million in 2025.
  • Its Net Cash Flow stands at -$4.1 million for Q3 2025, versus -$21.3 million for Q2 2025 and -$356.9 million for Q1 2025.